MHRA announced on 12 March 2026 that it approved deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults. The agency also stated that, as with any medicine, it will keep the safety and effectiveness of deuruxolitinib under close review.
For PV readers, the approval is significant not only because it expands treatment options, but because it also shows how regulators now often communicate approval and ongoing vigilance in the same message. That makes the safety-monitoring expectation explicit from the start.
Inference: this kind of wording reflects a more lifecycle-oriented regulatory tone, where market entry and continued surveillance are presented as part of one continuum rather than separate phases.
0 Comments